Literature DB >> 7429005

Erythromycin infusions for treatment of infections in the ear, nose and throat region.

H Blenk, B Blenk, G Jahneke, K Simm, B von Lucke, D LaFranier.   

Abstract

Sixteen adult male patients (aged between 20-38 years) with ear, nose and throat infections, caused by bacteria sensitive to erythromycin, received daily infusions of 2 x 1 g erythromycin for 48 hours. The duration of infusion was 30 or 60 minutes, administered at intervals of 12 hours between infusions. Symptoms of intolerance such as nausea, retching, feeling of pressure in epigastric angle as well as abdominal cramps occurred as side-effects in many cases. A spasmolytic was given intravenously to twelve patients; it rapidly eliminated the symptoms. However, these side-effects were considered insignificant compared to the excellent clinical results obtained during infusion therapy. We, therefore, believe that 2 x 1 g/day erythromycin per infusion can be regarded as the drug of choice in chronic and acute ear, nose and throat infections. The rapid resolution of infections, which are otherwise difficult to treat, and the concomitant decrease in confinement to bed by about 8 to 10 days are the most important results in this study.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7429005

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  3 in total

1.  Side-effects due to the intravenous infusion of erythromycin lactobionate.

Authors:  R Putzi; J Blaser; R Lüthy; R Wehrli; W Siegenthaler
Journal:  Infection       Date:  1983 May-Jun       Impact factor: 3.553

2.  Gastrointestinal motor-stimulating activity of macrolide antibiotics and analysis of their side effects on the canine gut.

Authors:  Z Itoh; T Suzuki; M Nakaya; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

3.  Gastrointestinal side effects after intravenous erythromycin lactobionate.

Authors:  K M Downey; D M Chaput de Saintonge
Journal:  Br J Clin Pharmacol       Date:  1986-03       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.